Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) will report third quarter 2025 financial results and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET.
Management will review the company's Q3 2025 financial results and deliver a corporate update. The live webcast is accessible under “Events and Presentations” on Arvinas' investor website and a replay will be available at www.arvinas.com after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ARVN gained 0.95%, reflecting a mild positive market reaction. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $746M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the third quarter of 2025 and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas (ARVN) report third quarter 2025 results?
How can I access the Arvinas (ARVN) November 5, 2025 webcast?
Will a replay of the Arvinas (ARVN) Q3 2025 webcast be available?
What will Arvinas management cover in the November 5, 2025 presentation?
What is the Arvinas stock ticker for investor searches?
